Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b):
SEC Accession No. 0001104659-25-042489
Filing Date
2025-04-30
Accepted
2025-04-30 16:05:35
Documents
15
Period of Report
2025-04-30
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K12B tm2513514d1_8k12b.htm   iXBRL 8-K12B 33858
2 EXHIBIT 99.1 tm2513514d1_ex99-1.htm EX-99.1 28469
  Complete submission text file 0001104659-25-042489.txt   300485

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA limn-20250430.xsd EX-101.SCH 3338
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE limn-20250430_def.xml EX-101.DEF 28644
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE limn-20250430_lab.xml EX-101.LAB 38277
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE limn-20250430_pre.xml EX-101.PRE 26853
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2513514d1_8k12b_htm.xml XML 6577
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: 8-K12B | Act: 34 | File No.: 001-42626 | Film No.: 25894936
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)